AGM
RDHL

Alpine Global Management’s Redhill Biopharma RDHL Stock Holding History

Alpine Global Management’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-65
Closed -$167K – 668
2021
Q4 		$167K Buy
+65
New +$260K 0.02% 493

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Alpine Global Management's RDHL Position: Q1 2022 in Review

Alpine Global Management sold out of Redhill Biopharma (RDHL) in Q1 2022, closing a stake of 65 shares — an estimated $167K sold.

Alpine Global Management first reported a position in RDHL in Q4 2021 and held it in 1 quarter. The position peaked at $167K in Q4 2021. 43 funds tracked by Wall St. Rank hold RDHL as of Q1 2022.

  • Alpine Global Management reported no remaining Redhill Biopharma position as of Q1 2022 after selling out during the quarter.
  • Alpine Global Management sold 65 Redhill Biopharma shares in Q1 2022, an estimated $167K.
  • Alpine Global Management first reported a position in Redhill Biopharma in Q4 2021 and held it in 1 quarter.
  • Alpine Global Management's Redhill Biopharma position peaked at $167K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.